



Appendix F

Analytical results of prescription-related outcomes with outliers included

Evaluation of the Pharmacist Care Clinic Pilot in
New Brunswick II

Impact on health outcomes and healthcare
resource utilization, and evaluation of client, staff,
and key stakeholder perceptions

November 2025

Note: This Appendix contains alternate versions of Tables 36-41, and Tables E11-E22, in which outlier values have not been removed. These alternate tables are named using the suffix “-F”, e.g., Table 36-F.

Table 1-F. Changes in prescription medication costs associated with pharmacy clinic visits.

Changes in all-cause prescription medication costs (dollars per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic costs [mean (95% CI)]	Post-clinic costs [mean (95% CI)]	p-value
Clinic clients (n = 160)	1592.46 (-277.02 – 3461.94)	439.19 (-159.14 – 1037.52)	0.20
Controls (n = 620)	293.10 (-32.64 – 618.84)	489.09 (-42.99 – 1021.18)	0.084
Difference-in-difference estimate: -1349.26			0.0072*
Changes in all-cause prescription medication costs (dollars per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic costs [mean (95% CI)]	Post-clinic costs [mean (95% CI)]	p-value
Clinic clients (n = 105)	1975.26 (-776.24 – 4726.77)	614.61 (-295.49 – 1524.72)	0.30
Controls (n = 405)	141.97 (92.05 – 191.88)	246.17 (111.29 – 381.06)	0.14
Difference-in-difference estimate: -1464.86			0.029*
Diabetes pharmacy clinic visits			
	Pre-clinic costs [mean (95% CI)]	Post-clinic costs [mean (95% CI)]	p-value
Clinic clients (n = 75)	694.82 (-295.31 – 1684.95)	217.70 (127.17 – 308.22)	0.34
Controls (n = 300)	470.53 (-199.47 – 1140.53)	766.59 (-321.33 – 1854.52)	0.18
Difference-in-difference estimate: -773.18			0.13

Table 2-F. Changes in prescription unit cost associated with pharmacy clinic visits.

Changes in all-cause prescription unit cost (dollars per unit dispensed) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic cost [mean (95% CI)]	Post-clinic cost [mean (95% CI)]	p-value
Clinic clients (n = 160)	2.96 (0.82 – 5.10)	1.15 (0.22 – 2.09)	0.021*
Controls (n = 620)	1.70 (0.41 – 3.00)	2.60 (0.90 – 4.31)	0.067
Difference-in-difference estimate: -2.71			0.01*
Changes in all-cause prescription unit cost (dollars per unit dispensed) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic cost [mean (95% CI)]	Post-clinic cost [mean (95% CI)]	p-value
Clinic clients (n = 105)	3.24 (0.30 – 6.17)	1.44 (0.02 – 2.86)	0.059
Controls (n = 405)	1.16 (0.63 – 1.70)	2.73 (0.96 – 4.50)	0.073
Difference-in-difference estimate: -3.36			0.061
Diabetes pharmacy clinic visits			
	Pre-clinic cost [mean (95% CI)]	Post-clinic cost [mean (95% CI)]	p-value
Clinic clients (n = 75)	2.37 (0.33 – 4.40)	1.04 (0.58 – 1.51)	0.18
Controls (n = 300)	2.49 (-0.12 – 5.10)	3.74 (0.43 – 7.05)	0.12
Difference-in-difference estimate: -2.57			0.12

Table 3-F. Changes in all-prescriber prescription volume associated with pharmacy clinic visits.

Changes in all-cause, all-prescriber prescription volume (prescriptions per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 160)	1.75 (1.47 – 2.02)	2.86 (2.44 – 3.27)	<0.0001*
Controls (n = 620)	1.69 (1.43 – 1.94)	2.17 (1.87 – 2.47)	<0.0001*
Difference-in-difference estimate: 0.62			<0.0001*
Changes in all-cause, all-prescriber prescription volume (prescriptions per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 105)	1.71 (1.39 – 2.04)	2.88 (2.38 – 3.38)	<0.0001*
Controls (n = 405)	1.79 (1.47 – 2.10)	2.35 (1.98 – 2.71)	<0.0001*
Difference-in-difference estimate: 0.61			<0.0001*
Diabetes pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 75)	2.21 (1.73 – 2.70)	3.40 (2.70 – 4.10)	<0.0001*
Controls (n = 300)	1.77 (1.35 – 2.20)	2.21 (1.72 – 2.71)	<0.0001*
Difference-in-difference estimate: 0.75			0.0003*

Table 4-F. Changes in physician/nurse practitioner prescription volume associated with pharmacy clinic visits.

Changes in all-cause physician/nurse practitioner prescription volume (prescriptions per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 160)	1.47 (1.23 – 1.72)	1.62 (1.26 – 1.99)	0.18
Controls (n = 620)	1.61 (1.36 – 1.86)	2.07 (1.77 – 2.37)	<0.0001*
Difference-in-difference estimate: -0.31			0.014*
Changes in all-cause physician/nurse practitioner prescription volume (prescriptions per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 105)	1.42 (1.15 – 1.69)	1.58 (1.15 – 2.01)	0.25
Controls (n = 405)	1.71 (1.41 – 2.01)	2.23 (1.88 – 2.59)	<0.0001*
Difference-in-difference estimate: -0.36			0.015*
Diabetes pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 75)	1.84 (1.42 – 2.27)	2.00 (1.39 – 2.62)	0.36
Controls (n = 300)	1.71 (1.30 – 2.12)	2.11 (1.62 – 2.60)	<0.0001*
Difference-in-difference estimate: -0.23			0.24

Table 5-F. Changes in pharmacist prescription volume associated with pharmacy clinic visits.

Changes in all-cause pharmacist prescription volume (prescriptions per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 160)	0.27 (0.19 – 0.35)	1.23 (1.01 – 1.45)	<0.0001*
Controls (n = 620)	0.075 (0.053 – 0.098)	0.10 (0.074 – 0.13)	0.12
Difference-in-difference estimate: 0.93			<0.0001*
Changes in all-cause pharmacist prescription volume (prescriptions per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 105)	0.30 (0.18 – 0.41)	1.30 (1.02 – 1.58)	<0.0001*
Controls (n = 405)	0.076 (0.055 – 0.097)	0.11 (0.074 – 0.15)	0.074
Difference-in-difference estimate: 0.97			<0.0001*
Diabetes pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 75)	0.37 (0.21 – 0.53)	1.40 (1.03 – 1.76)	<0.0001*
Controls (n = 300)	0.066 (0.041 – 0.090)	0.11 (0.064 – 0.15)	0.077
Difference-in-difference estimate: 0.98			<0.0001*

Table 6-F. Changes in all-prescriber prescription units dispensed associated with pharmacy clinic visits.

Changes in all-cause, all-prescriber prescription units dispensed (units dispensed per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic units [mean (95% CI)]	Post-clinic units [mean (95% CI)]	p-value
Clinic clients (n = 160)	464.99 (-171.77 – 1101.74)	218.78 (189.47 – 248.09)	0.45
Controls (n = 620)	120.77 (104.95 – 136.59)	150.38 (134.95 – 165.82)	<0.0001*
Difference-in-difference estimate: -275.82			0.091
Changes in all-cause, all-prescriber prescription units dispensed (units dispensed per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic units [mean (95% CI)]	Post-clinic units [mean (95% CI)]	p-value
Clinic clients (n = 105)	630.44 (-337.81 – 1598.68)	219.26 (181.68 – 256.84)	0.40
Controls (n = 405)	131.46 (109.72 – 153.19)	158.58 (139.23 – 177.93)	0.0036*
Difference-in-difference estimate: -438.31			0.076
Diabetes pharmacy clinic visits			
	Pre-clinic units [mean (95% CI)]	Post-clinic units [mean (95% CI)]	p-value
Clinic clients (n = 75)	172.75 (140.52 – 204.98)	251.11 (210.57 – 291.64)	<0.0001*
Controls (n = 300)	116.40 (99.32 – 133.49)	153.91 (131.33 – 176.48)	<0.0001*
Difference-in-difference estimate: 40.85			0.013*

Table E11-F. Changes in prescription medication costs associated with pharmacy clinic visits among one-time clinic users.

Changes in all-cause prescription medication costs (dollars per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic costs [mean (95% CI)]	Post-clinic costs [mean (95% CI)]	p-value
Clinic clients (n = 110)	1707.48 (-794.86 – 4209.83)	106.85 (61.96 – 151.75)	0.21
Controls (n = 435)	116.41 (72.02 – 160.79)	243.78 (109.03 – 378.52)	0.068
Difference-in-difference estimate: -1728.00			0.0078*
Changes in all-cause prescription medication costs (dollars per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic costs [mean (95% CI)]	Post-clinic costs [mean (95% CI)]	p-value
Clinic clients (n = 70)	2107.41 (-1711.52 – 5926.34)	115.32 (46.84 – 183.80)	0.30
Controls (n = 275)	154.71 (85.92 – 223.49)	302.02 (106.15 – 497.90)	0.15
Difference-in-difference estimate: -2139.41			0.030*
Diabetes pharmacy clinic visits			
	Pre-clinic costs [mean (95% CI)]	Post-clinic costs [mean (95% CI)]	p-value
Clinic clients (n = 45)	936.68 (-675.21 – 2548.58)	190.28 (89.81 – 290.76)	0.35
Controls (n = 185)	97.65 (41.86 – 153.45)	227.49 (23.05 – 431.93)	0.23
Difference-in-difference estimate: -876.24			0.054

Note: Pre- and post-clinic prescription costs among clinic clients and matched controls were compared using paired *t*-tests, with the resultant *p*-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant *p*-value shown in the rightmost column. *P*-values of <0.05 (marked *) are considered to be statistically significant.

Table E12-F. Changes in prescription medication costs associated with pharmacy clinic visits among repeat clinic users.

Changes in all-cause prescription medication costs (dollars per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic costs [mean (95% CI)]	Post-clinic costs [mean (95% CI)]	p-value
Clinic clients (n = 45)	1317.42 (-913.31 – 3548.14)	1233.91 (-828.75 – 3296.57)	0.44
Controls (n = 180)	719.70 (-392.32 – 1831.71)	1081.36 (-715.18 – 2877.90)	0.30
Difference-in-difference estimate: -445.17			0.52
Changes in all-cause prescription medication costs (dollars per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic costs [mean (95% CI)]	Post-clinic costs [mean (95% CI)]	p-value
Clinic clients (n = 35)	1694.95 (-1447.50 – 4837.40)	1673.71 (-1233.90 – 4581.32)	0.86
Controls (n = 130)	114.61 (60.11 – 169.11)	126.24 (67.58 – 184.91)	0.11
Difference-in-difference estimate: -32.87			0.60
Diabetes pharmacy clinic visits			
	Pre-clinic costs [mean (95% CI)]	Post-clinic costs [mean (95% CI)]	p-value
Clinic clients (n = 25)	302.83 (29.04 – 576.62)	262.13 (81.83 – 442.43)	0.72
Controls (n = 115)	1078.92 (-692.78 – 2850.61)	1646.18 (-1216.85 – 4509.21)	0.31
Difference-in-difference estimate: -607.97			0.58

Note: Pre- and post-clinic prescription costs among clinic clients and matched controls were compared using paired *t*-tests, with the resultant *p*-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant *p*-value shown in the rightmost column. *P*-values of <0.05 (marked *) are considered to be statistically significant.

Table E13-F. Changes in prescription unit cost associated with pharmacy clinic visits among one-time clinic users.

Changes in all-cause prescription unit cost (dollars per unit dispensed) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic cost [mean (95% CI)]	Post-clinic cost [mean (95% CI)]	p-value
Clinic clients (n = 110)	2.42 (0.52 – 4.32)	0.64 (0.36 – 0.92)	0.062
Controls (n = 435)	0.92 (0.49 – 1.36)	1.63 (0.63 – 2.62)	0.17
Difference-in-difference estimate: -2.48			0.028*
Changes in all-cause prescription unit cost (dollars per unit dispensed) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic cost [mean (95% CI)]	Post-clinic cost [mean (95% CI)]	p-value
Clinic clients (n = 70)	2.54 (0.25 – 4.83)	0.67 (0.27 – 1.07)	0.095
Controls (n = 275)	1.17 (0.51 – 1.84)	2.01 (0.58 – 3.44)	0.26
Difference-in-difference estimate: -2.71			0.085
Diabetes pharmacy clinic visits			
	Pre-clinic cost [mean (95% CI)]	Post-clinic cost [mean (95% CI)]	p-value
Clinic clients (n = 45)	2.59 (-0.54 – 5.73)	1.04 (0.41 – 1.67)	0.31
Controls (n = 185)	0.74 (0.34 – 1.14)	1.40 (0.11 – 2.69)	0.34
Difference-in-difference estimate: -2.21			0.16

*Note: Pre- and post-clinic prescription unit cost among clinic clients and matched controls were compared using paired t-tests, with the resultant p-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant p-value shown in the rightmost column. P-values of <0.05 (marked *) are considered to be statistically significant.*

Table E14-F. Changes in prescription unit cost associated with pharmacy clinic visits among repeat clinic users.

Changes in all-cause prescription unit cost (dollars per unit dispensed) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic cost [mean (95% CI)]	Post-clinic cost [mean (95% CI)]	p-value
Clinic clients (n = 45)	4.27 (-1.54 – 10.07)	2.38 (-0.78 – 5.53)	0.18
Controls (n = 180)	3.59 (-0.73 – 7.90)	4.96 (-0.38 – 10.30)	0.23
Difference-in-difference estimate: -3.26			0.17
Changes in all-cause prescription unit cost (dollars per unit dispensed) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic cost [mean (95% CI)]	Post-clinic cost [mean (95% CI)]	p-value
Clinic clients (n = 35)	4.71 (-3.37 – 12.78)	3.07 (-1.40 – 7.54)	0.37
Controls (n = 130)	1.14 (0.24 – 2.03)	4.28 (-0.39 – 8.95)	0.16
Difference-in-difference estimate: -4.78			0.29
Diabetes pharmacy clinic visits			
	Pre-clinic cost [mean (95% CI)]	Post-clinic cost [mean (95% CI)]	p-value
Clinic clients (n =25)	2.00 (0.09 – 3.90)	1.05 (0.33 – 1.77)	0.31
Controls (n = 115)	5.34 (-1.53 – 12.21)	7.56 (-0.92 – 16.04)	0.22
Difference-in-difference estimate: -3.17			0.38

*Note: Pre- and post-clinic prescription unit cost among clinic clients and matched controls were compared using paired t-tests, with the resultant p-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant p-value shown in the rightmost column. P-values of <0.05 (marked *) are considered to be statistically significant.*

Table E15-F. Changes in all-prescriber prescription volume associated with pharmacy clinic visits among one-time clinic users.

Changes in all-cause, all-prescriber prescription volume (prescriptions per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 110)	1.56 (1.28 – 1.85)	2.37 (1.96 – 2.79)	<0.0001*
Controls (n = 435)	1.59 (1.36 – 1.83)	2.04 (1.76 – 2.32)	<0.0001*
Difference-in-difference estimate: 0.31			0.012*
Changes in all-cause, all-prescriber prescription volume (prescriptions per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 70)	1.52 (1.21 – 1.84)	2.32 (1.87 – 2.78)	<0.0001*
Controls (n = 275)	1.72 (1.41 – 2.02)	2.27 (1.89 – 2.65)	<0.0001*
Difference-in-difference estimate: 0.24			0.19
Diabetes pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 45)	1.94 (1.41 – 2.47)	2.86 (2.09 – 3.63)	<0.0001*
Controls (n = 185)	1.64 (1.30 – 1.98)	2.00 (1.59 – 2.40)	0.0051
Difference-in-difference estimate: 0.56			0.037*

*Note: Pre- and post-clinic prescription volumes among clinic clients and matched controls were compared using paired t-tests, with the resultant p-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant p-value shown in the rightmost column. P-values of <0.05 (marked *) are considered to be statistically significant.*

Table E16-F. Changes in all-prescriber prescription volume associated with pharmacy clinic visits among repeat clinic users.

Changes in all-cause, all-prescriber prescription volume (prescriptions per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 45)	2.19 (1.55 – 2.84)	4.01 (3.08 – 4.94)	<0.0001*
Controls (n = 185)	1.91 (1.25 – 2.58)	2.49 (1.70 – 3.28)	<0.0001*
Difference-in-difference estimate: 1.24			<0.0001*
Changes in all-cause, all-prescriber prescription volume (prescriptions per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 35)	2.12 (1.35 – 2.89)	4.07 (2.89 – 5.25)	<0.0001*
Controls (n = 130)	1.94 (1.19 – 2.68)	2.50 (1.68 – 3.33)	<0.0001*
Difference-in-difference estimate: 1.38			<0.0001*
Diabetes pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 25)	2.65 (1.68 – 3.62)	4.28 (2.93 – 5.62)	<0.0001*
Controls (n = 115)	1.99 (1.02 – 2.97)	2.57 (1.43 – 3.71)	<0.0001*
Difference-in-difference estimate: 1.05			0.0010*

*Note: Pre- and post-clinic prescription volumes among clinic clients and matched controls were compared using paired t-tests, with the resultant p-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant p-value shown in the rightmost column. P-values of <0.05 (marked *) are considered to be statistically significant.*

Table E17-F. Changes in physician/nurse practitioner prescription volume associated with pharmacy clinic visits among one-time clinic users.

Changes in all-cause physician/NP prescription volume (prescriptions per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 110)	1.34 (1.06 – 1.62)	1.42 (1.02 – 1.83)	0.50
Controls (n = 435)	1.52 (1.29 – 1.74)	1.93 (1.66 – 2.20)	<0.0001*
Difference-in-difference estimate: -0.33			0.026*
Changes in all-cause physician/NP prescription volume (prescriptions per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n= 70)	1.28 (0.98 – 1.59)	1.24 (0.82 – 1.66)	0.78
Controls (n = 275)	1.64 (1.34 – 1.94)	2.15 (1.78 – 2.51)	<0.0001*
Difference-in-difference estimate: -0.55			0.0024*
Diabetes pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n= 45)	1.66 (1.15 – 2.17)	1.68 (0.95 – 2.42)	0.91
Controls (n = 185)	1.57 (1.25 – 1.90)	1.87 (1.49 – 2.26)	0.011*
Difference-in-difference estimate: -0.28			0.28

*Note: Pre- and post-clinic prescription volumes among clinic clients and matched controls were compared using paired t-tests, with the resultant p-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant p-value shown in the rightmost column. P-values of <0.05 (marked *) are considered to be statistically significant.*

Table E18-F. Changes in physician/nurse practitioner prescription volume associated with pharmacy clinic visits among repeat clinic users.

Changes in all-cause physician/NP prescription volume (prescriptions per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 45)	1.80 (1.28 – 2.32)	2.10 (1.34 – 2.87)	0.19
Controls (n = 185)	1.84 (1.19 – 2.49)	2.41 (1.62 – 3.19)	<0.0001*
Difference-in-difference estimate: -0.26			0.28
Changes in all-cause physician/NP prescription volume (prescriptions per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n= 35)	1.70 (1.14 – 2.26)	2.32 (1.32 – 3.31)	0.030*
Controls (n = 130)	1.85 (1.14 – 2.56)	2.42 (1.60 – 3.24)	<0.0001*
Difference-in-difference estimate: 0.046			0.86
Diabetes pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n= 25)	2.14 (1.36 – 2.91)	2.53 (1.40 – 3.65)	0.23
Controls (n = 115)	1.93 (0.99 – 2.88)	2.49 (1.36 – 3.62)	0.0002*
Difference-in-difference estimate: -0.17			0.61

*Note: Pre- and post-clinic prescription volumes among clinic clients and matched controls were compared using paired t-tests, with the resultant p-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant p-value shown in the rightmost column. P-values of <0.05 (marked *) are considered to be statistically significant.*

Table E19-F. Changes in pharmacist prescription volume associated with pharmacy clinic visits among one-time clinic users.

Changes in all-cause pharmacist prescription volume (prescriptions per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 110)	0.22 (0.15 – 0.30)	0.95 (0.73 – 1.17)	<0.0001*
Controls (n = 435)	0.077 (0.048 – 0.11)	0.11 (0.073 – 0.15)	0.15
Difference-in-difference estimate: 0.70			<0.0001*
Changes in all-cause pharmacist prescription volume (prescriptions per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 70)	0.24 (0.13 – 0.35)	1.09 (0.77 – 1.41)	<0.0001*
Controls (n = 275)	0.072 (0.051 – 0.092)	0.12 (0.073 – 0.17)	0.042*
Difference-in-difference estimate: 0.79			<0.0001*
Diabetes pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 45)	0.28 (0.12 – 0.45)	1.18 (0.73 – 1.63)	<0.0001*
Controls (n = 185)	0.069 (0.041 – 0.097)	0.12 (0.065 – 0.18)	0.068
Difference-in-difference estimate: 0.84			<0.0001*

*Note: Pre- and post-clinic prescription volumes among clinic clients and matched controls were compared using paired t-tests, with the resultant p-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant p-value shown in the rightmost column. P-values of <0.05 (marked *) are considered to be statistically significant.*

Table E20-F. Changes in pharmacist prescription volume associated with pharmacy clinic visits among repeat clinic users.

Changes in all-cause pharmacist prescription volume (prescriptions per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n =45)	0.39 (0.19 – 0.60)	1.90 (1.41 – 2.39)	<0.0001*
Controls (n = 185)	0.072 (0.037 – 0.11)	0.086 (0.043 – 0.13)	0.60
Difference-in-difference estimate: 1.50			<0.0001*
Changes in all-cause pharmacist prescription volume (prescriptions per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 35)	0.42 (0.14 – 0.69)	1.75 (1.21 – 2.30)	<0.0001*
Controls (n = 130)	0.085 (0.037 – 0.13)	0.086 (0.042 – 0.13)	0.99
Difference-in-difference estimate: 1.34			<0.0001*
Diabetes pharmacy clinic visits			
	Pre-clinic volume [mean (95% CI)]	Post-clinic volume [mean (95% CI)]	p-value
Clinic clients (n = 25)	0.51 (0.19 – 0.84)	1.75 (1.12 – 2.39)	0.0001*
Controls (n = 115)	0.061 (0.014 – 0.11)	0.078 (0.021 – 0.13)	0.63
Difference-in-difference estimate: 1.22			<0.0001*

*Note: Pre- and post-clinic prescription volumes among clinic clients and matched controls were compared using paired t-tests, with the resultant p-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant p-value shown in the rightmost column. P-values of <0.05 (marked *) are considered to be statistically significant.*

Table E21-F. Changes in all-prescriber prescription units dispensed associated with pharmacy clinic visits among one-time clinic users.

Changes in all-cause, all-prescriber prescription units dispensed (units dispensed per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic units [mean (95% CI)]	Post-clinic units [mean (95% CI)]	p-value
Clinic clients (n = 110)	584.02 (-322.09 – 1490.13)	177.58 (148.96 – 206.19)	0.38
Controls (n = 435)	124.01 (103.64 – 144.38)	144.93 (128.14 – 161.71)	0.016*
Difference-in-difference estimate: -427.37			0.064
Changes in all-cause, all-prescriber prescription units dispensed (units dispensed per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic units [mean (95% CI)]	Post-clinic units [mean (95% CI)]	p-value
Clinic clients (n = 70)	837.45 (-595.83 – 2270.72)	165.35 (131.50 – 199.20)	0.35
Controls (n = 275)	135.26 (106.40 – 164.12)	155.79 (134.20 – 177.38)	0.11
Difference-in-difference estimate: -692.63			0.056
Diabetes pharmacy clinic visits			
	Pre-clinic units [mean (95% CI)]	Post-clinic units [mean (95% CI)]	p-value
Clinic clients (n = 45)	151.84 (116.95 – 186.74)	218.12 (172.46 – 263.79)	<0.0001*
Controls (n = 185)	122.44 (100.06 – 144.82)	151.47 (124.77 – 178.17)	0.0002*
Difference-in-difference estimate: 37.25			0.024*

Note: Pre- and post-clinic prescription units dispensed among clinic clients and matched controls were compared using paired t-tests, with the resultant p-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant p-value shown in the rightmost column. P-values of <0.05 (marked *) are considered to be statistically significant.

Table E22-F. Changes in all-prescriber prescription units dispensed associated with pharmacy clinic visits among repeat clinic users.

Changes in all-cause, all-prescriber prescription units dispensed (units dispensed per person-month) associated with overall pharmacy clinic visits (for any chronic disease)			
	Pre-clinic units [mean (95% CI)]	Post-clinic units [mean (95% CI)]	p-value
Clinic clients (n = 45)	180.34 (133.33 – 227.36)	317.31 (251.80 – 382.83)	<0.0001*
Controls (n = 180)	112.95 (90.35 – 135.55)	163.55 (129.64 – 197.46)	<0.0001*
Difference-in-difference estimate: 86.37			0.0005*
Changes in all-cause, all-prescriber prescription units dispensed (units dispensed per person-month) associated with cause-specific pharmacy clinic visits			
CVD pharmacy clinic visits			
	Pre-clinic units [mean (95% CI)]	Post-clinic units [mean (95% CI)]	p-value
Clinic clients (n = 35)	191.32 (128.71 – 253.94)	333.60 (250.79 – 416.42)	<0.0001*
Controls (n = 130)	123.29 (93.85 – 152.73)	164.57 (124.65 – 204.49)	<0.0001*
Difference-in-difference estimate: 101.00			<0.0001*
Diabetes pharmacy clinic visits			
	Pre-clinic units [mean (95% CI)]	Post-clinic units [mean (95% CI)]	p-value
Clinic clients (n = 25)	206.64 (142.82 – 270.46)	304.56 (228.72 – 380.40)	0.0018*
Controls (n = 115)	106.55 (79.98 – 133.12)	157.89 (116.95 – 198.83)	0.001
Difference-in-difference estimate: 46.58			0.16

Note: Pre- and post-clinic prescription units dispensed among clinic clients and matched controls were compared using paired t-tests, with the resultant p-value shown in the rightmost column. The difference-in-difference regression estimate reflects the change in the clinic client group mean value after adjusting for the change in the matched control group mean value, with the resultant p-value shown in the rightmost column. P-values of <0.05 (marked *) are considered to be statistically significant.